Valeant Provides Financial Guidance Update

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced updated financial guidance for the fourth quarter and full year 2015 as well as new guidance for full year 2016.

“We are very excited about the strong future given our broad portfolio of brands, our upcoming launch products and our robust R&D pipeline,” said J. Michael Pearson, chairman and chief executive officer. “We believe that we are entering a new era of growth and opportunity as we continue to build and grow our businesses around the world and deliver medicines and products at affordable prices that improve the lives of patients.”

Full Year 2016 Guidance

  • Total Revenue $12.5 – $12.7 billion
  • Adjusted EBITDA* $6.9 – $7.1 billion
  • Adjusted non-GAAP EPS* $13.25 -$13.75
  • Double Digit Same Store Sales Organic Growth – primarily driven through volume
  • Expect to reduce debt by ~$2.25 billion, including mandatory payments and maturities
  • Expect net leverage ratio to be ~4.0 times pro forma adjusted EBITDA by the end of 2016

Q4 2015 Revised Guidance

  • Total Revenues previously $3.25 – $3.45 billion now $2.7 – $2.8 billion
  • Adjusted EPS* previously $4.00 – $4.20 now $2.55 -$2.65
  • Adjusted Cash Flow from Operations* previously greater than $1.0 billion, now greater than $600 million

Full Year 2015 Revised Guidance

  • Total Revenue previously $11.0 – $11.2 billion now $10.4 -$10.5 billion
  • Adjusted EPS* previously $11.67 – $11.87 now $10.23 -$10.33
  • Adjusted Cash Flow from Operations* previously greater than $3.35 billion, now greater than $2.95 billion

SOURCE Valeant Pharmaceuticals International, Inc.